Oxygen therapy

Search ⌘K Suggest Edit Sign in Overview Clinical Applications Physiological Effects Delivery Methods Sources, Storage, and Safety Clinical Guidelines and Advances References Fact-checked by Grok 5 months ago Oxygen therapy Oxygen therapy is the administration of supplemental oxygen to patients experiencing hypoxemia, a condition where blood oxygen levels fall below normal, to maintain adequate tissue oxygenation and prevent complications such as organ damage from hypoxia.[1] This treatment supports cellular respiration and vital organ function, particularly in individuals with respiratory or cardiac conditions that impair natural oxygen uptake.[1] It is delivered via various devices to achieve target oxygen saturation levels, typically 92%-98% for most patients or 88%-92% for those with chronic hypercapnic respiratory failure.[1] Indications for oxygen therapy include acute and chronic hypoxemia caused by conditions such as pneumonia, chronic obstructive pulmonary disease (COPD), pulmonary embolism, sepsis, and sleep apnea, as well as during high-altitude exposure or post-surgical recovery.[1][2] In vulnerable populations, including infants, pregnant individuals, and the elderly, it is essential for managing respiratory distress from illnesses like COVID-19 or trauma.[3] Globally, oxygen therapy plays a pivotal role in healthcare, potentially preventing up to 122,000 annual childhood deaths from pneumonia if access were improved, though fewer than half of facilities in low- and middle-income countries have reliable supplies.[3] Common methods of administration include low-flow systems like nasal cannulas (delivering 1-6 liters per minute for 24%-40% fractional inspired oxygen, or FiO₂) and simple face masks (5-10 liters per minute for 40%-60% FiO₂), as well as high-flow options such as non-rebreather masks (10-15 liters per minute for up to 80% FiO₂) and oxygen concentrators that extract oxygen from ambient air.[1] Oxygen sources encompass compressed gas cylinders, liquid oxygen systems for portability, and concentrator machines powered by electricity or batteries.[2] Benefits include reduced shortness of breath, enhanced energy and activity tolerance, and better sleep quality, allowing patients to maintain daily functions despite underlying lung diseases like emphysema.[2] While effective, oxygen therapy carries risks, including oxygen toxicity from prolonged high concentrations, which can cause chest pain, dizziness, or lung damage, and fire hazards due to oxygen's ability to accelerate combustion.[2] Side effects may involve dry nasal passages, nosebleeds, or headaches, necessitating careful monitoring of oxygen levels to avoid over-supplementation.[2] Supplemental oxygen is not addictive; the common myth that patients can become addicted to it, including within 7 days or at any time, is unfounded. Worsening of symptoms upon discontinuation results from the underlying hypoxemia rather than addiction or withdrawal.[4][5] Historically, unmonitored use in preterm infants led to the discovery of retinopathy of prematurity in the 1940s, underscoring the need for precise dosing.[1] Overview Definition and principles Oxygen therapy is defined as the administration of supplemental oxygen at concentrations exceeding that of room air (21%, or FiO2 of 0.21) through various delivery devices to correct or prevent hypoxemia and ensure adequate tissue oxygenation.[1] This intervention aims to maintain arterial oxygen partial pressure (PaO2) above 60 mmHg and oxygen saturation (SaO2 or SpO2) within target ranges, typically 92-98% for most patients, thereby supporting cellular metabolism and preventing hypoxic organ damage.[1][6] The primary physiological principle underlying oxygen therapy is the correction of hypoxemia, which occurs when oxygen delivery to tissues is insufficient to meet metabolic demands. Hypoxemia is classified into four main types: hypoxic (due to low PaO2 from reduced inspired oxygen or impaired gas exchange), anemic (from decreased oxygen-carrying capacity, such as low hemoglobin), stagnant (from reduced blood flow, as in circulatory failure), and histotoxic (from impaired cellular oxygen utilization, as in cyanide poisoning).[7][8] Supplemental oxygen primarily addresses hypoxic hypoxemia by increasing the fraction of inspired oxygen (FiO2), which elevates alveolar and arterial PO2, thereby improving oxygen diffusion into the blood and subsequent binding to hemoglobin.[7] It has limited efficacy for the other types, as they stem from issues beyond oxygen availability in the lungs.[7] A key aspect of these principles is the oxygen-hemoglobin dissociation curve, which describes the sigmoidal relationship between PaO2 and hemoglobin saturation (SaO2), reflecting hemoglobin's cooperative binding of oxygen. The curve's position is characterized by the P50 value, the PaO2 at which hemoglobin is 50% saturated, normally approximately 26-27 mmHg under standard conditions (pH 7.4, PCO2 40 mmHg, temperature 37°C).[9][10] In hypoxemia, supplemental oxygen shifts the operating point along the curve to higher saturation levels, enhancing oxygen loading in the lungs without altering the P50 itself.[9] Normal oxygen consumption at rest is approximately 250 mL/min for an average adult, met primarily through blood delivery where oxygen is transported bound to hemoglobin (up to 1.34 mL O2 per gram of hemoglobin) and a minor dissolved fraction (0.003 mL O2/dL blood per mmHg PaO2).[11][12] Key measurements include FiO2 (expressed as a decimal or percentage, indicating inspired oxygen fraction), PaO2 (arterial partial pressure in mmHg, assessed via arterial blood gas), and SaO2 (arterial oxygen saturation percentage, estimated noninvasively as SpO2 via pulse oximetry).[1] These parameters guide therapy titration to balance efficacy and risks.[1] Historical development The discovery of oxygen in the late 18th century laid the foundation for its eventual medical applications. Swedish chemist Carl Wilhelm Scheele first isolated oxygen between 1771 and 1772 through experiments heating mercuric oxide and other compounds, though his findings were published later. Independently, English theologian and chemist Joseph Priestley isolated oxygen in 1774 by heating mercuric oxide, describing it as "dephlogisticated air" that supported combustion and respiration more vigorously than ordinary air. French chemist Antoine Lavoisier, building on these works in the late 1770s, named the gas "oxygen" from the Greek words for "acid former" and recognized its essential role in respiration and combustion, overturning the phlogiston theory.[13][14][15] Medical adoption of oxygen therapy began tentatively in the late 18th and 19th centuries, initially for conditions like pneumonia and cyanosis. In 1799, British physician Thomas Beddoes established the Pneumatic Institution in Bristol to explore "factitious airs," including oxygen, for treating pulmonary diseases such as pneumonia, with early anecdotal reports of benefits in alleviating cyanosis. Throughout the 19th century, oxygen was administered via inhalation or dissolution in water for respiratory ailments, though its use remained limited by production challenges and lack of standardized delivery; physiological studies, such as those by John Scott Haldane in the early 1900s, confirmed oxygen's role in reversing hypoxemia in cyanotic patients. By the early 20th century, clinical trials demonstrated improved outcomes in pneumonia cases with cyanosis when oxygen was supplied continuously.[16][13][16] The 20th century marked rapid advancements in oxygen delivery technologies and applications. In the 1920s, oxygen tents emerged as a practical method for enclosing patients to maintain high oxygen concentrations, pioneered by researchers like Alvan L. Barach for treating severe respiratory distress. The 1930s saw oxygen therapy extend to aviation, with the U.S. military developing high-altitude masks to combat hypoxia in pilots, as exemplified by the 1938 BLB mask from Mayo Clinic researchers. Hyperbaric oxygen applications also began in the 1930s for decompression sickness in divers. The 1950s introduced positive-pressure mechanical ventilators, such as the Bird Mark 7, enabling precise oxygen delivery during surgery and polio epidemics. Home oxygen therapy transformed in the 1970s with the invention of oxygen concentrators, which extracted oxygen from ambient air, allowing ambulatory use and reducing reliance on cylinders. The 1980s solidified long-term oxygen therapy (LTOT) through trials like the Nocturnal Oxygen Therapy Trial (NOTT) in 1980, which demonstrated survival benefits in chronic obstructive pulmonary disease; this informed early British Thoracic Society (BTS) recommendations on LTOT assessment and prescription.[17][18][19][20][21][22] In the 21st century, oxygen therapy evolved toward more conservative practices amid evidence of hyperoxia risks. The 2010s featured key trials, such as the 2016 Oxygen-ICU randomized trial, which showed that conservative oxygen targets reduced mortality compared to liberal use in critically ill patients, highlighting harms like oxidative stress and organ dysfunction from excessive oxygen. The COVID-19 pandemic from 2020 to 2023 accelerated adoption of high-flow nasal cannula (HFNC) therapy, which provided humidified oxygen at flows up to 60 L/min, reducing intubation rates in hypoxemic respiratory failure; observational studies reported improved outcomes in 52% of severe cases without progression to mechanical ventilation.[23][24][25] Globally, the World Health Organization (WHO) launched the Oxygen Access Scale-Up Initiative in 2021, aiming to enhance production, supply chains, and training in low-resource settings through 2025, including a 2023 World Health Assembly resolution to triple access and save an estimated 800,000 lives annually by addressing inequities in medical oxygen availability.[26][3] As of 2025, ongoing WHO efforts include virtual workshops for national medical oxygen scale-up plans, while technological advancements feature new stationary oxygen concentrators like the Inogen Voxi 5, improving affordability and durability for home therapy.[3][27] Clinical Applications Indications for acute conditions Oxygen therapy serves as a cornerstone intervention in acute medical emergencies to address severe hypoxemia, defined as arterial oxygen partial pressure (PaO2) below 60 mmHg or peripheral oxygen saturation (SpO2) below 90%, thereby preventing organ dysfunction and supporting vital functions. Primary indications include hypoxemic respiratory failure arising from conditions such as pneumonia, acute respiratory distress syndrome (ARDS), and pulmonary embolism, where supplemental oxygen restores adequate tissue oxygenation and stabilizes hemodynamics.[28][29] In these scenarios, oxygen administration mitigates the rapid progression of respiratory compromise, with clinical guidelines emphasizing prompt initiation to target SpO2 levels of 92-98% in most patients without chronic hypercapnia.[30] During cardiac arrest, high-concentration oxygen is commonly administered as part of advanced life support protocols to maximize oxygen delivery to ischemic tissues, with retrospective studies suggesting benefits from higher intra-arrest oxygenation levels, though the 2025 American Heart Association guidelines do not specify a particular fraction of inspired oxygen (FiO2) concentration.[31] Similarly, in trauma associated with shock, such as hemorrhagic or hypovolemic states, oxygen is indicated to counteract tissue hypoxia secondary to reduced perfusion, with British Thoracic Society guidelines specifying initial high-flow delivery via reservoir mask at 15 L/min for major trauma and shock.[32] For carbon monoxide poisoning, 100% normobaric oxygen accelerates carboxyhemoglobin elimination, reducing its half-life from 4-6 hours on room air to approximately 1 hour, thereby limiting neurological sequelae.[33] Specific acute scenarios further delineate oxygen use, including exacerbations of chronic obstructive pulmonary disease (COPD), where controlled administration targets SpO2 of 88-92% to avoid hypercapnic respiratory failure while correcting hypoxemia.[34] Perioperative hypoxemia, often due to atelectasis or ventilation-perfusion mismatch post-anesthesia, warrants supplemental oxygen to maintain SpO2 above 92%, as routine postoperative administration has been shown to reduce complication rates.[35] Post-extubation support in critically ill patients at risk of respiratory failure similarly employs oxygen, with high-flow nasal cannula preferred over conventional methods to improve oxygenation and prevent reintubation.[36] Evidence from randomized controlled trials underscores oxygen's role in acute settings, including its integration into sepsis management protocols where supplemental oxygen for hypoxemic patients contributes to improved outcomes, as supported by analyses of severe sepsis cohorts showing associations with reduced short-term mortality when avoiding hyperoxia.[37] In ST-elevation myocardial infarction (STEMI), the 2025 ACC/AHA guidelines recommend oxygen only for hypoxemia (SpO2 <90%), titrated to achieve SpO2 ≥90%, based on trials demonstrating no benefit—and potential harm—from routine use in normoxemic patients.[38] Dosing typically begins with a high fraction of inspired oxygen (FiO2) of 0.5-1.0 via mask or ventilator to rapidly achieve targets, followed by titration downward to the lowest effective level, with therapy often limited to less than 48 hours in resolving acute episodes to minimize risks.[39] Indications for chronic conditions Long-term oxygen therapy (LTOT) is primarily indicated for patients with chronic respiratory diseases experiencing persistent hypoxemia, defined as a partial pressure of arterial oxygen (PaO2) ≤55 mmHg or oxygen saturation (SpO2) ≤88% at rest on room air.[40] This therapy aims to alleviate symptoms, improve survival, and enhance quality of life in stable, non-acute settings. The seminal Nocturnal Oxygen Therapy Trial (NOTT) in 1980 demonstrated that continuous oxygen administration for more than 15 hours per day reduced mortality by approximately 40% in hypoxemic chronic obstructive pulmonary disease (COPD) patients compared to nocturnal use alone, establishing a benchmark for LTOT duration.[41] Similarly, the 1981 Medical Research Council (MRC) trial confirmed a survival benefit with at least 15 hours of daily oxygen in COPD patients with severe hypoxemia, influencing current guidelines.[42] In COPD, LTOT is recommended for those meeting the hypoxemia criteria, particularly with evidence of cor pulmonale, polycythemia, or peripheral edema, as per American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines.[40] For interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), indications align with similar hypoxemia thresholds, with LTOT prescribed to mitigate exertional desaturation and right heart strain; the ATS endorses at least 15 hours daily for severe chronic hypoxemia in ILD.[43] Cystic fibrosis patients qualify for LTOT when resting PaO2 ≤55 mmHg or during sleep/exercise desaturation occurs, supporting lung function preservation.[44] Pulmonary hypertension secondary to lung disease warrants LTOT for PaO2 ≤55 mmHg or ≤59 mmHg with cor pulmonale, aiming to reduce pulmonary vascular resistance.[45] Assessment for LTOT involves arterial blood gas analysis to confirm resting hypoxemia, supplemented by polysomnography to detect sleep-related desaturation, which affects up to 50% of candidates and may necessitate nocturnal augmentation.[40] Exercise testing, such as the 6-minute walk test with continuous oximetry, identifies desaturation below 88% during activity, guiding ambulatory oxygen needs even if resting levels are borderline.[46] LTOT regimens typically involve continuous delivery (19-24 hours/day) for optimal survival benefits in severe cases, outperforming nocturnal-only (6-8 hours) as shown in NOTT, though nocturnal suffices for isolated sleep hypoxemia.[41] Portable oxygen concentrators or liquid systems enable ambulation, improving adherence and daily function.[47] Weaning is considered annually or upon clinical improvement, via repeat blood gas testing to ensure PaO2 >60 mmHg off oxygen without desaturation.[40] In heart failure with Cheyne-Stokes respiration, nocturnal LTOT corrects cyclic hypoxemia, enhancing exercise capacity and cognitive function by stabilizing ventilation.[48] For sickle cell disease, chronic hypoxemia from pulmonary complications qualifies patients for LTOT to prevent vaso-occlusive events and organ damage.[49] Outcomes of LTOT include prolonged survival (e.g., median extension of 1-2 years in COPD) and better quality of life through reduced dyspnea and increased activity tolerance.[42] In non-COPD applications like IPF, 2023 ATS updates affirm improved exercise parameters and health-related quality of life, though survival gains are modest compared to COPD; ongoing 2025 research emphasizes earlier initiation for ILD to optimize palliative benefits.[43][40] Contraindications Oxygen therapy, while beneficial in many hypoxic states, carries risks that necessitate careful patient selection to avoid harm. Absolute contraindications exist in scenarios where oxygen administration could directly exacerbate the underlying condition or lead to life-threatening complications. One such absolute contraindication is paraquat poisoning, where supplemental oxygen worsens pulmonary fibrosis by promoting the generation of reactive oxygen species that amplify lung injury.[50] Similarly, uncomplicated hypercapnic respiratory failure without concomitant hypoxemia, such as in pure CO2 retainers, represents an absolute contraindication, as high-flow oxygen can suppress hypoxic drive, leading to apnea and further respiratory decompensation.[51] Relative contraindications require individualized assessment, where the potential benefits must be weighed against risks, often with modified dosing or alternative therapies. Untreated pneumothorax is a relative contraindication, particularly with positive pressure oxygen delivery systems, due to the risk of tension pneumothorax from air expansion in the pleural space.[52] In patients with chronic obstructive pulmonary disease (COPD) experiencing acute hypercapnia, oxygen therapy should be used cautiously with targeted pulse oximetry (SpO2) levels of 88-92% to prevent worsening hypercapnia and acidosis, as per British Thoracic Society (BTS) guidelines (2017).[51] For cancer patients with prior bleomycin exposure, high fractional inspired oxygen (FiO2) concentrations exceeding 0.5 are relatively contraindicated due to heightened risk of bleomycin-induced pneumonitis and pulmonary fibrosis.[53] In at-risk patients, such as those with hypercapnic conditions, serial arterial blood gas (ABG) monitoring is essential to titrate oxygen and detect rising PaCO2 levels early. Non-invasive ventilation (NIV) is often preferred over high-flow oxygen in hypercapnic respiratory failure to provide ventilatory support without excessive oxygenation. Special considerations apply in neonates, where unrestricted oxygen therapy increases the risk of retinopathy of prematurity (ROP) through vascular endothelial growth factor dysregulation in immature retinas; thus, strict SpO2 targets (typically 90-95%) and oximetry monitoring are recommended. Additionally, oxygen-enriched environments pose fire hazards, contraindicating therapy in settings with open flames, smoking, or flammable materials, as oxygen accelerates combustion and elevates burn risk.[54][55] Adverse effects Oxygen therapy, while essential for managing hypoxemia, can lead to several adverse clinical effects, particularly when administered at high concentrations or for prolonged durations. Common pulmonary effects include oxygen toxicity, which manifests as cough and substernal chest tightness, typically after exposure to a fraction of inspired oxygen (FiO2) greater than 0.6 for over 24 hours.[56] Another frequent complication is absorption atelectasis, resulting from nitrogen washout in the alveoli, which causes ventilation-perfusion (V/Q) mismatch and reduced lung compliance, often observed in patients receiving high-flow oxygen.[57] Additionally, dry delivery of oxygen can irritate the nasal and oral mucosa, leading to discomfort, epistaxis, or sore throat in up to 10-20% of patients using nasal cannulas.[58] Serious risks associated with oxygen therapy include retinopathy of prematurity (formerly retrolental fibroplasia) in preterm infants, where exposure to FiO2 levels above 0.4 increases the incidence of severe retinal vascular damage, potentially leading to blindness if not monitored closely.[59] Environmental hazards pose another concern, as oxygen-enriched atmospheres significantly heighten fire and explosion risks—fires burn up to five times faster and more intensely in such settings, contributing to injuries or fatalities in healthcare and home environments.[2] Abrupt withdrawal of supplemental oxygen can also precipitate rebound hypoxemia, characterized by a sudden drop in oxygen saturation below baseline levels, particularly in patients with chronic lung disease, which may exacerbate respiratory distress.[60] It is a common misconception that such worsening symptoms indicate addiction to supplemental oxygen; reliable medical sources confirm that supplemental oxygen is not addictive and does not cause physical or psychological dependence. Any deterioration upon discontinuation is due to the underlying condition causing low blood oxygen levels, rather than withdrawal from addiction.[61][4] Hyperoxia from routine oxygen supplementation has been linked to worsened clinical outcomes in specific acute conditions. In patients with suspected acute myocardial infarction, the AVOID trial demonstrated that high-flow oxygen (6-8 L/min) in normoxic individuals increased myocardial infarct size compared to ambient air, signaling potential harm without mortality differences in the primary analysis.[62] Similarly, in acute stroke, hyperoxemia (SpO2 >96%) is associated with higher risks of poor neurological outcomes and mortality, as shown in a 2025 systematic review of patients with acute brain injury.[63] Monitoring for adverse effects involves vigilant observation of symptoms such as nausea, visual disturbances (e.g., blurred vision or myopia), and respiratory changes, which can indicate evolving oxygen toxicity.[56] Routine pulse oximetry and arterial blood gas assessments help detect hyperoxia early, with nasal irritation reported in 10-20% of long-term nasal cannula users.[1] To mitigate these risks, clinicians should administer the lowest effective oxygen dose to maintain SpO2 at 92-95% in most adults, titrating based on individual needs to avoid unnecessary hyperoxia.[1] Humidification of inspired gases is recommended for flows exceeding 4 L/min or durations over 24 hours to prevent mucosal drying and associated complications.[1] Gradual weaning protocols further reduce the likelihood of rebound hypoxemia.[60] Physiological Effects Beneficial mechanisms Supplemental oxygen therapy primarily benefits patients in hypoxemic states by elevating arterial partial pressure of oxygen (PaO₂) and arterial oxygen saturation (SaO₂), thereby augmenting systemic oxygen delivery to tissues.[12] This enhancement occurs as supplemental oxygen increases the fraction of inspired oxygen (FiO₂), driving more oxygen into the bloodstream via alveolar diffusion and binding to hemoglobin.[1] The overall oxygen delivery (DO₂) is quantified by the formula: 𝐷 𝑂 2 = 𝐶 𝑂 × ( 𝐻 𝑏 × 1.34 × 𝑆 𝑎 𝑂 2 + 0.003 × 𝑃 𝑎 𝑂 2 ) DO 2 ​

=CO×(Hb×1.34×SaO 2 ​

+0.003×PaO 2 ​

) where CO represents cardiac output, Hb is hemoglobin concentration, and the term 0.003 × PaO₂ accounts for dissolved oxygen in plasma.[12] In acidosis, a rightward shift of the oxyhemoglobin dissociation curve further facilitates oxygen unloading at the tissue level by reducing hemoglobin's affinity for oxygen, promoting efficient release in metabolically active areas.[64] At the cellular level, increased oxygen availability supports aerobic respiration, enabling oxidative phosphorylation in mitochondria to generate adenosine triphosphate (ATP) as the primary energy source.[12] This shift from anaerobic glycolysis minimizes lactate production and accumulation, which otherwise occurs during oxygen-limited states and contributes to metabolic acidosis.[65] By restoring aerobic metabolism, supplemental oxygen preserves cellular function and prevents energy deficits in hypoxemic conditions.[1] Organ-specific benefits include improved myocardial contractility during ischemia, where enhanced oxygen delivery counteracts reduced coronary blood flow and supports contractile performance.[66] In the brain, supplemental oxygen aids cerebral blood flow autoregulation under hypoxic stress by normalizing oxygen supply, thereby stabilizing perfusion without excessive vasodilation.[67] The Fick principle underpins these effects, describing oxygen consumption (VO₂) as: 𝑉 𝑂 2 = 𝐶 𝑂 × ( 𝐶 𝑎 𝑂 2 − 𝐶 𝑣 𝑂 2 ) VO 2 ​

=CO×(CaO 2 ​

−CvO 2 ​

) where CaO₂ and CvO₂ are arterial and venous oxygen contents, respectively; supplemental oxygen increases CaO₂, allowing sustained VO₂ despite hypoxemia.[68] Clinical studies demonstrate that raising FiO₂ can significantly improve tissue oxygenation in hypoxemic patients.[1] However, oxygen therapy has limitations in non-hypoxemic forms of tissue hypoxia, such as anemia, where reduced hemoglobin impairs oxygen-carrying capacity; in these cases, transfusion is required rather than oxygen supplementation alone.[69] Pulmonary effects Oxygen therapy exerts beneficial effects on pulmonary function by addressing hypoxemia-related derangements. In conditions involving ventilation-perfusion (V/Q) mismatch, supplemental oxygen reverses hypoxic pulmonary vasoconstriction (HPV), a physiological response that diverts blood flow from poorly ventilated alveoli to better-oxygenated regions.[70] This reversal enhances overall V/Q matching, thereby improving arterial oxygenation and reducing the work of breathing in hypoxemic patients.[71] Additionally, hyperoxia can attenuate exercise-induced bronchospasm in asthmatic individuals by modulating carotid body-mediated reflexes, leading to mild bronchodilation and reduced airway constriction during acute exacerbations.[72] However, prolonged or high-concentration oxygen administration can induce detrimental pulmonary changes, particularly absorption atelectasis. This occurs when high fractional inspired oxygen (FiO₂ > 0.5) for durations exceeding 12 hours replaces alveolar nitrogen with rapidly absorbed oxygen, causing uneven gas resorption and subsequent alveolar collapse in underventilated regions.[70] Airway inflammation represents another adverse effect, where exposure to high FiO₂ generates reactive oxygen species that damage ciliated epithelium, impairing mucociliary clearance; this risk escalates after 48 hours of elevated oxygen levels.[56] Such inflammation contributes to oxidative injury in the tracheobronchial tree, exacerbating respiratory compromise in vulnerable patients.[73] Key mechanisms underlying these negative effects include inhibition of pulmonary surfactant synthesis and function by hyperoxia, which elevates alveolar surface tension and promotes collapse.[74] High FiO₂ can also transiently increase airway resistance through direct irritant effects on bronchial smooth muscle and mucosal edema, though this is less pronounced than in hypoxic states.[75] In mechanically ventilated patients, absorption atelectasis is common (up to 90%), correlating with reduced lung compliance and prolonged ventilator dependence, though high FiO₂ does not significantly increase incidence compared to moderate levels.[76] Clinical evidence supports strategies to mitigate these risks. The ARDS Network trial of 2000 demonstrated that limiting FiO₂ through a structured PEEP-FiO₂ titration table reduced atelectasis formation and improved outcomes in acute respiratory distress syndrome by prioritizing alveolar recruitment over high oxygen concentrations. As of 2025, intensive care unit trends emphasize conservative oxygenation targets (PaO₂ 70-100 mmHg) combined with adequate PEEP to prevent atelectasis and toxicity while maintaining efficacy.[77] In specialized contexts like diving, pulmonary oxygen toxicity manifests distinctly under hyperbaric conditions. At partial pressures exceeding 1.6 atmospheres absolute (ATA), symptoms such as irritative cough and tracheobronchial irritation emerge due to direct oxidant damage to lung parenchyma, limiting safe exposure durations in technical divers.[78] Systemic effects Oxygen therapy exerts significant influences on non-pulmonary systems, particularly the cardiovascular and neurological systems, with effects that can be both beneficial and detrimental depending on dosage and duration. In the cardiovascular system, supplemental oxygen induces pulmonary vasodilation, which reduces pulmonary vascular resistance and alleviates strain on the right ventricle, particularly in patients with pulmonary hypertension or right heart failure.[79] This selective vasodilatory action improves cardiac index and overall hemodynamics without substantially affecting systemic pressures.[80] However, hyperoxia often leads to systemic vasoconstriction, notably in coronary and renal arteries, mediated by the generation of reactive oxygen species and free radicals that promote endothelial dysfunction.[81] This vasoconstriction can reduce myocardial and renal blood flow, increasing afterload and potentially exacerbating ischemia in vulnerable patients.[66] Furthermore, in ischemic conditions such as acute coronary syndrome, hyperoxia heightens the risk of reperfusion injury through excessive oxidative stress upon restoration of blood flow.[82] Neurologically, prolonged exposure to high partial pressures of oxygen, typically exceeding 2 atmospheres absolute (ATA), can precipitate central nervous system toxicity, manifesting as symptoms including tremors, nausea, vertigo, and in severe cases, seizures.[56] These effects arise from oxidative damage to neural tissues and are more pronounced during hyperbaric oxygen therapy.[83] Additionally, chronic oxygen therapy suppresses erythropoietin (EPO) production by reducing hypoxia-inducible factors in the kidneys, leading to diminished erythropoiesis and a gradual decline in hemoglobin levels, often by 10-15% after several weeks of continuous administration. This hematological impact underscores the need for monitoring in long-term therapy scenarios. Other systemic repercussions include the potential for hypercapnia in patients prone to CO2 retention, such as those with chronic obstructive pulmonary disease. The Haldane effect—where oxygenated hemoglobin binds CO2 less avidly—shifts the CO2 dissociation curve, resulting in an elevated arterial partial pressure of CO2 (PaCO2) by approximately 5-10 mmHg in susceptible individuals.[84] Retinal vasoconstriction is another notable effect of hyperoxia, which constricts retinal vessels to regulate oxygen delivery and maintain constant retinal oxygen tension, potentially affecting visual function with prolonged exposure.[85] These systemic effects are particularly evident at inspired oxygen fractions (FiO2) greater than 0.6 or with exposures exceeding 24 hours, as supported by the 2025 American Heart Association (AHA) guidelines on acute coronary syndromes, which caution against routine supplemental oxygen in normoxic patients due to hyperoxia-induced vasoconstriction and increased infarct size.[86][87] Careful titration of oxygen to maintain normoxia is thus essential to mitigate these risks while preserving therapeutic benefits. Oxidative and immunological effects Oxygen therapy, particularly when involving hyperoxia (elevated fractional inspired oxygen, FiO2), can induce oxidative stress through the overproduction of reactive oxygen species (ROS). In hyperoxic conditions, mitochondrial electron transport chains leak electrons to molecular oxygen, generating superoxide anion (O₂⁻•) and subsequently hydrogen peroxide (H₂O₂) as primary ROS. These species overwhelm cellular antioxidant defenses, leading to lipid peroxidation of cell membranes and oxidative damage to DNA, which contributes to cellular dysfunction and long-term toxicity. Toxicity typically manifests when FiO2 exceeds 0.5 for more than 16 hours, with thresholds around FiO2 ≥0.6 accelerating ROS-mediated injury.[88][89][90][91] Prolonged hyperoxia also exerts immunological effects by impairing innate immune responses. Exposure to high oxygen levels disrupts neutrophil function, reducing their ability to phagocytose and kill bacteria such as Klebsiella pneumoniae, despite initial increases in ROS production for microbicidal activity. This leads to overall immunosuppression, elevating the risk of secondary infections; for instance, hyperoxemia has been linked to a higher incidence of ventilator-associated pneumonia (VAP) in critically ill patients, with studies indicating up to a 20% increased sepsis risk during extended therapy. In septic patients, hyperoxia exacerbates outcomes through immune dysregulation and oxidative damage to immune cells.[92][93][94][95] At the molecular level, hyperoxia activates protective pathways like the Nrf2-antioxidant response element (ARE) signaling, where Nrf2 translocates to the nucleus to upregulate genes encoding antioxidants such as glutathione peroxidase and superoxide dismutase, mitigating ROS-induced damage. However, chronic exposure depletes key antioxidants, including vitamins E and C, which are consumed in neutralizing peroxyl radicals and superoxide, respectively, further exacerbating oxidative imbalance. Nrf2 knockout models demonstrate heightened susceptibility to hyperoxic injury, underscoring its role in cellular adaptation.[96][97][98] Evidence from animal models highlights these effects, with neonatal mice exposed to hyperoxia showing increased lung fibrosis upon subsequent bleomycin challenge, including up to 30% greater fibrotic deposition due to persistent oxidative damage. Human studies, including 2024 reviews of critically ill cohorts, confirm that hyperoxia correlates with VAP development via impaired bacterial clearance and heightened inflammation, independent of underlying lung pathology.[99][95] Mitigation strategies focus on minimizing oxidative burden through the use of the lowest effective FiO2 to maintain target saturations (e.g., 88-92% in COPD patients), alongside antioxidant supplementation. N-acetylcysteine (NAC), a glutathione precursor, reduces ROS levels and improves outcomes in hyperoxia-exposed models by scavenging H₂O₂ and restoring thiol balance, with clinical trials showing decreased inflammatory markers in ventilated patients.[100][101][102] Delivery Methods Low-flow delivery systems Low-flow delivery systems are non-invasive devices that deliver supplemental oxygen at rates below the patient's peak inspiratory flow, typically 20–40 L/min, making them suitable for mild hypoxemia where precise control of fraction of inspired oxygen (FiO₂) is not always critical. These systems rely on ambient air dilution, resulting in variable FiO₂ based on patient breathing patterns, and are commonly used in stable clinical settings.[1] The nasal cannula, a lightweight device with prongs inserted into the nostrils, operates at flow rates of 1-6 L/min and delivers FiO₂ of 0.24-0.44. A common clinical approximation holds that each 1 L/min increase raises FiO₂ by about 4% above room air (0.21), though actual values vary with tidal volume and respiratory rate. The simple face mask, which covers the nose and mouth, functions at 5-10 L/min to provide FiO₂ of 0.35-0.50, while the Venturi mask entrains room air through color-coded adapters to achieve precise FiO₂ of 0.24-0.60 at total flows up to 50 L/min or more.[1][100][103] These systems operate on the principle of partial oxygen supplementation, where delivered oxygen mixes with inspired room air; in Venturi masks, the Bernoulli effect creates a high-velocity jet that entrains air at fixed ratios for consistent FiO₂, such as 1:3 (oxygen:air) for approximately 35% FiO₂. Efficacy can diminish with mouth breathing, as oxygen escapes without nasal inhalation, and flows exceeding 4 L/min necessitate humidification to mitigate nasal or airway dryness. Minimum flows of 5 L/min are required for face masks to flush exhaled carbon dioxide and prevent rebreathing.[103][1][104] Indications for low-flow systems include management of stable chronic hypoxemia, such as in patients with chronic obstructive pulmonary disease requiring long-term oxygen therapy, and short-term support during postoperative recovery to maintain adequate saturation without invasive intervention.[1] Advantages include high patient tolerance due to their unobtrusive design, low cost, and suitability for ambulatory or home use, allowing activities of daily living. Limitations encompass inconsistent FiO₂ delivery in non-Venturi devices due to variable entrainment, risk of CO₂ rebreathing in masks at flows below 5 L/min leading to hypercapnia, and reduced performance in patients with high inspiratory demands or mouth breathing.[1][103][104] As of 2025, portable oxygen concentrators integrated with low-flow systems, such as nasal cannulas, provide 90-95% purity oxygen from ambient air for home and mobile use, improving accessibility for chronic conditions while adhering to medical standards for continuous low-flow delivery.[105] High-flow and positive pressure systems High-flow nasal cannula (HFNC) systems deliver heated and humidified oxygen at flow rates up to 60 L/min with a fraction of inspired oxygen (FiO₂) ranging from 0.21 to 1.0, providing support that meets or exceeds patient inspiratory demands to prevent entrainment of room air.[106] These systems reduce anatomical dead space through continuous high-flow washout of expired carbon dioxide from the nasopharynx and oropharynx, enhancing alveolar ventilation efficiency.[107] Additionally, HFNC generates low levels of positive end-expiratory pressure (PEEP), typically 2-5 cmH₂O, which aids in alveolar recruitment and reduces work of breathing by decreasing inspiratory resistance.[108] This makes HFNC particularly useful in acute hypoxemic respiratory failure, where it improves oxygenation and patient comfort compared to conventional oxygen delivery.[106] Positive pressure systems, including continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP), apply noninvasive pressures of 5-20 cmH₂O to maintain airway patency and recruit collapsed alveoli, preventing atelectasis while allowing variable FiO₂ titration.[109] CPAP delivers constant pressure throughout the respiratory cycle, whereas BiPAP provides higher inspiratory pressure (IPAP) and lower expiratory pressure (EPAP), with IPAP typically 10-20 cmH₂O and EPAP 4-10 cmH₂O, supporting ventilation in conditions like acute cardiogenic pulmonary edema or mild acute respiratory distress syndrome (ARDS).[110] For more severe cases requiring invasive support, mechanical ventilation via endotracheal intubation uses modes such as synchronized intermittent mandatory ventilation (SIMV), where FiO₂ and PEEP are titrated to achieve adequate oxygenation while minimizing ventilator-induced lung injury.[111] SIMV synchronizes mandatory breaths with patient efforts, delivering set tidal volumes (often 6 mL/kg predicted body weight) and rates, with PEEP levels adjusted (e.g., 5-15 cmH₂O) to optimize end-expiratory lung volume.[112] These systems are indicated for acute respiratory distress, including ARDS and post-extubation support, where high-flow matching and pres